Merck Spin-Off Prexton Turns mGluR4 Fortunes Around In Parkinson's Disease

Prexton Therapeutics has the only mGluR4-targeting drug candidate in clinical testing, after a number of big pharma dropped preclinical programs. The company has just secured €29m to fund two Phase II trials.